Short Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Declines By 9.9%

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 4,540,000 shares, a drop of 9.9% from the January 15th total of 5,040,000 shares. Based on an average daily volume of 429,700 shares, the short-interest ratio is presently 10.6 days. Currently, 18.5% of the shares of the stock are sold short.

Arcturus Therapeutics Trading Up 10.0 %

ARCT traded up $1.64 during trading on Friday, reaching $18.05. 842,108 shares of the company traded hands, compared to its average volume of 362,393. The firm has a fifty day simple moving average of $17.01 and a 200 day simple moving average of $18.95. Arcturus Therapeutics has a 12-month low of $14.30 and a 12-month high of $45.00.

Institutional Trading of Arcturus Therapeutics

Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new position in shares of Arcturus Therapeutics during the third quarter valued at about $191,000. nVerses Capital LLC purchased a new position in Arcturus Therapeutics during the 3rd quarter valued at about $42,000. China Universal Asset Management Co. Ltd. raised its position in shares of Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after acquiring an additional 2,038 shares in the last quarter. Empire Life Investments Inc. acquired a new position in Arcturus Therapeutics during the third quarter worth approximately $3,498,000. Finally, ARK Investment Management LLC increased its holdings in shares of Arcturus Therapeutics by 6.9% in the third quarter. ARK Investment Management LLC now owns 2,101,038 shares of the biotechnology company’s stock valued at $48,765,000 after purchasing an additional 136,074 shares during the period. 94.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. BTIG Research started coverage on shares of Arcturus Therapeutics in a research report on Tuesday, January 28th. They issued a “buy” rating and a $41.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Friday. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $65.00.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.